Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Constitution amended to include environmental and health protection: A model for Europe.
Piscitelli P, Costa S, Costa A, Emiliano M, Caputo N, Schittulli F, Bonabello M, Pollice F, Uricchio AF, Scanio AP, Miani A. Piscitelli P, et al. Among authors: schittulli f. Lancet Reg Health Eur. 2022 Apr 4;16:100367. doi: 10.1016/j.lanepe.2022.100367. eCollection 2022 May. Lancet Reg Health Eur. 2022. PMID: 35403079 Free PMC article. No abstract available.
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M. Vici P, et al. Among authors: schittulli f. Ann Oncol. 2012 May;23(5):1121-1129. doi: 10.1093/annonc/mdr412. Epub 2011 Sep 28. Ann Oncol. 2012. PMID: 21965475 Free PMC article. Clinical Trial.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Amadori D, et al. Among authors: schittulli f. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. doi: 10.1007/s10549-010-1257-5. Epub 2010 Dec 4. Breast Cancer Res Treat. 2011. PMID: 21132360 Free article. Clinical Trial.
Association between mode of breast cancer detection and diagnosis delay.
Crispo A, Montella M, Barba M, Schittulli F, De Marco MR, Grimaldi M, Quaranta M, Serravezza G, Savastano C, Botti G, La Vecchia C, D'Aiuto G. Crispo A, et al. Among authors: schittulli f. Breast. 2009 Dec;18(6):382-6. doi: 10.1016/j.breast.2009.10.001. Epub 2009 Oct 30. Breast. 2009. PMID: 19879761 Free article.
BRCA1 expression and molecular alterations in familial breast cancer.
Mangia A, Chiriatti A, Tommasi S, Menolascina F, Petroni S, Zito FA, Simone G, Schittulli F, Paradiso A. Mangia A, et al. Among authors: schittulli f. Histol Histopathol. 2009 Jan;24(1):69-76. doi: 10.14670/HH-24.69. Histol Histopathol. 2009. PMID: 19012246
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA. Zhang Y, et al. Among authors: schittulli f. Breast Cancer Res Treat. 2009 Jul;116(2):303-9. doi: 10.1007/s10549-008-0183-2. Epub 2008 Sep 23. Breast Cancer Res Treat. 2009. PMID: 18821012 Clinical Trial.
82 results